An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway
High-density lipoprotein (HDL) is believed to play an important role in lowering cardiovascular disease (CVD) risk by mediating the process of reverse cholesterol transport (RCT). Via RCT, excess cholesterol from peripheral tissues is carried back to the liver and hence should lead to the reduction...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 13, 2014
|
| In: |
PLoS Computational Biology
Year: 2014, Jahrgang: 10 |
| ISSN: | 1553-7358 |
| DOI: | 10.1371/journal.pcbi.1003509 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pcbi.1003509 Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1003509 
|
| Verfasserangaben: | James Lu, Katrin Hübner, M. Nazeem Nanjee, Eliot A. Brinton, Norman A. Mazer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1726741990 | ||
| 003 | DE-627 | ||
| 005 | 20230427082120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200811s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pcbi.1003509 |2 doi | |
| 035 | |a (DE-627)1726741990 | ||
| 035 | |a (DE-599)KXP1726741990 | ||
| 035 | |a (OCoLC)1341354871 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Lu, James |e VerfasserIn |0 (DE-588)1215619804 |0 (DE-627)172674079X |4 aut | |
| 245 | 1 | 3 | |a An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway |c James Lu, Katrin Hübner, M. Nazeem Nanjee, Eliot A. Brinton, Norman A. Mazer |
| 264 | 1 | |c March 13, 2014 | |
| 300 | |a 26 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.08.2020 | ||
| 520 | |a High-density lipoprotein (HDL) is believed to play an important role in lowering cardiovascular disease (CVD) risk by mediating the process of reverse cholesterol transport (RCT). Via RCT, excess cholesterol from peripheral tissues is carried back to the liver and hence should lead to the reduction of atherosclerotic plaques. The recent failures of HDL-cholesterol (HDL-C) raising therapies have initiated a re-examination of the link between CVD risk and the rate of RCT, and have brought into question whether all target modulations that raise HDL-C would be atheroprotective. To help address these issues, a novel in-silico model has been built to incorporate modern concepts of HDL biology, including: the geometric structure of HDL linking the core radius with the number of ApoA-I molecules on it, and the regeneration of lipid-poor ApoA-I from spherical HDL due to remodeling processes. The ODE model has been calibrated using data from the literature and validated by simulating additional experiments not used in the calibration. Using a virtual population, we show that the model provides possible explanations for a number of well-known relationships in cholesterol metabolism, including the epidemiological relationship between HDL-C and CVD risk and the correlations between some HDL-related lipoprotein markers. In particular, the model has been used to explore two HDL-C raising target modulations, Cholesteryl Ester Transfer Protein (CETP) inhibition and ATP-binding cassette transporter member 1 (ABCA1) up-regulation. It predicts that while CETP inhibition would not result in an increased RCT rate, ABCA1 up-regulation should increase both HDL-C and RCT rate. Furthermore, the model predicts the two target modulations result in distinct changes in the lipoprotein measures. Finally, the model also allows for an evaluation of two candidate biomarkers for in-vivo whole-body ABCA1 activity: the absolute concentration and the % lipid-poor ApoA-I. These findings illustrate the potential utility of the model in drug development. | ||
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Cholesteryl esters | |
| 650 | 4 | |a Heterozygosity | |
| 650 | 4 | |a Homozygosity | |
| 650 | 4 | |a Lipids | |
| 650 | 4 | |a Lipoproteins | |
| 650 | 4 | |a Simulation and modeling | |
| 700 | 1 | |a Hübner, Katrin |d 1975- |e VerfasserIn |0 (DE-588)136669476 |0 (DE-627)58545793X |0 (DE-576)30119937X |4 aut | |
| 700 | 1 | |a Nanjee, M. Nazeem |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brinton, Eliot A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mazer, Norman A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a Public Library of Science |t PLoS Computational Biology |d San Francisco, Calif. : Public Library of Science, 2005 |g 10(2014) Artikel-Nummer e1003509, 26 Seiten |h Online-Ressource |w (DE-627)491436017 |w (DE-600)2193340-6 |w (DE-576)273890492 |x 1553-7358 |7 nnas |
| 773 | 1 | 8 | |g volume:10 |g year:2014 |g extent:26 |a An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pcbi.1003509 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1003509 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200811 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 136669476 |a Hübner, Katrin |m 136669476:Hübner, Katrin |d 700000 |d 721000 |e 700000PH136669476 |e 721000PH136669476 |k 0/700000/ |k 1/700000/721000/ |p 2 | ||
| 999 | |a KXP-PPN1726741990 |e 3737952558 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 11.08.2020"],"language":["eng"],"recId":"1726741990","title":[{"title_sort":"in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway","title":"An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway"}],"person":[{"family":"Lu","given":"James","roleDisplay":"VerfasserIn","display":"Lu, James","role":"aut"},{"display":"Hübner, Katrin","roleDisplay":"VerfasserIn","role":"aut","family":"Hübner","given":"Katrin"},{"family":"Nanjee","given":"M. Nazeem","roleDisplay":"VerfasserIn","display":"Nanjee, M. Nazeem","role":"aut"},{"role":"aut","display":"Brinton, Eliot A.","roleDisplay":"VerfasserIn","given":"Eliot A.","family":"Brinton"},{"roleDisplay":"VerfasserIn","display":"Mazer, Norman A.","role":"aut","family":"Mazer","given":"Norman A."}],"physDesc":[{"extent":"26 S."}],"relHost":[{"title":[{"title_sort":"PLoS Computational Biology","subtitle":"a new community journal","title":"PLoS Computational Biology"}],"recId":"491436017","language":["eng"],"corporate":[{"display":"Public Library of Science","roleDisplay":"VerfasserIn","role":"aut"}],"disp":"Public Library of SciencePLoS Computational Biology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 23. November 2020"],"part":{"extent":"26","text":"10(2014) Artikel-Nummer e1003509, 26 Seiten","volume":"10","year":"2014"},"pubHistory":["1.2005 -"],"name":{"displayForm":["publ. by the Public Library of Science (PLoS) in association with the International Society for Computational Biology (ISCB)"]},"id":{"zdb":["2193340-6"],"eki":["491436017"],"issn":["1553-7358"]},"origin":[{"dateIssuedDisp":"2005-","dateIssuedKey":"2005","publisher":"Public Library of Science","publisherPlace":"San Francisco, Calif."}],"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedKey":"2014","dateIssuedDisp":"March 13, 2014"}],"id":{"doi":["10.1371/journal.pcbi.1003509"],"eki":["1726741990"]},"name":{"displayForm":["James Lu, Katrin Hübner, M. Nazeem Nanjee, Eliot A. Brinton, Norman A. Mazer"]}} | ||
| SRT | |a LUJAMESHUEINSILICOMO1320 | ||